Stocks · News reference
Autolus Therapeutics Reports Preliminary Q2 AUCATZYL Sales Of ~$45M; Raises FY2026 Sales Guidance From $120M-$135M To $140M-$150M
Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-dateFY 2026 sales guidance increased to $140 – $150 million, from $120 – $135
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Autolus Therapeutics plc (AUTL)
Filed: 2026-08-11 AccNo: 0001730463-26-000119 Size: 4 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Autolus Therapeutics Affirms FY2026 Sales Guidance of $140.000M-$150.000M vs $136.669M Est
Autolus Therapeutics (NASDAQ:AUTL) affirms FY2026 sales outlook from $140.000 million-$150.000 million to $140.000 million-$150.000 million vs $136.669 million estimate.
Autolus Therapeutics Q2 EPS $(0.15) Beats $(0.23) Estimate, Sales $45.689M Beat $34.016M Estimate
Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 34.78 percent. This is a 16.67 percent increase over losses of $(0.18) per share